Cigna Group (CI) Stock Price & Analysis
Cigna Group (CI) rose 0.00% to USD 289.57 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
CI last closed at USD 289.57; the session ranged USD 285.93–290.57 on volume of 855,665 shares. Market capitalization is —, with a 52-week range of USD 239.51–315.47 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 289.57 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 289.57 |
| Open | USD 289.57 |
| Day Range | USD 285.93 – 290.57 |
| 52-Week Range | USD 239.51 – 315.47 |
| Volume | 855,665 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (CI)
Nexqual's technical model rates CI "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 50.89 (neutral) |
| vs SMA50 | Above (USD 286.56) |
| MACD | 0.64 (positive) |
From Cigna Group's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our formulary management   services support clients in establishing formularies that assist customers and physicians in choosing clinically appropriate, cost-effective drugs and prioritize access, safety and affordability. ▪ We administer specific formularies for our clients, including standard formularies developed by Express Scripts ® Pharmacy Benefit Services ("Express Scripts") and custom formularies in which we play a more limited role.
- Health System Services includes CuraScript SD by Evernorth ® , which is a specialty distributor of pharmaceuticals and medical supplies (including injectable and infusible pharmaceuticals and medications to treat specialty and rare or orphan diseases) directly to health care providers, including clinics and hospitals in the United States for office or clinic administration.
- We use these patents to protect our proprietary technological advances and to differentiate ourselves in the market.
- Our ability to deliver this broad array of health care services on either a standalone or combined basis between its two operating segments enables us to drive incremental growth.
Partnerships
- Through our clinical programs and partnership with EviCore, we guide care to the most appropriate settings, reducing unnecessary costs while preserving quality and service, and offer virtual care options, including MD Live, to improve convenience and access.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HUM | Humana Inc. | USD 389.32 | ▼ 2.08% |
| CNC | Centene Corporation | USD 63.41 | ▼ 3.76% |
| HCA | HCA Healthcare, Inc. | USD 382.19 | ▲ 2.78% |
| CAH | Cardinal Health, Inc. | USD 228.03 | ▲ 3.4% |
| MCK | McKesson Corporation | USD 840.9 | ▲ 3.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.